ClinicalTrials.gg
RecruitingNCT05727397Updated Aug 31, 2023

Efficacy and Safety of RC28-E Versus Aflibercept

A Phase 3 interventional study of RC28-E and Aflibercept in Wet Age-related Macular Degeneration, sponsored by RemeGen Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2023-08-31.

Sponsored by RemeGen Co., Ltd. · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Nov 2025, 11 months ago, but the record still lists the study as recruiting.
  • Started Mar 2023; still recruiting 3 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
432
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 106 studies in Macular Degeneration with a site in China — 36 open to participants now, 43 under way, 9 of them phase 3. Macular Degeneration · China.

Planned enrollment
10th of 91
432 · median 62
Started
2023
with 13 others
Phase 3
18 of 106
4 open now
Primary completion
2025-11
later than 10 of 42 live
Registered
65th of 106
by date
Lead sponsor
3 of 106
RemeGen Co., Ltd.

Among the 106 studies in Macular Degeneration with a site in China, this one is the 10th largest by planned enrollment of the 91 interventional ones that give a count, is one of 14 that started in 2023, is one of 18 in phase 3, reaches primary completion later than 10 of the 42 other live ones, and was the 65th registered.

Macular Degeneration

1,459 studies on the registry are indexed under Macular Degeneration; 236 are open to participants now.

Browse Macular Degeneration studies →

Open to participants now

36 of the 106 studies in Macular Degeneration with a site in China are open now. Recruiting first, the newest first:

31 more — sign in →

All 36 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 165 Macular Degeneration studies recruiting now, 116 (70%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 106 studies in Macular Degeneration with a site in China, or all of them as a file.
02

Study summary

This is a randomized, double-masked, multicenter study comparing the the efficacy and safety of RC28-E injection (a chimric decoy receptor trap fusion protein by dual blockage of VEGF and FGF-2) versus aflibercept in patients with wet age-related macular degeneration.

03

Conditions studied

  • Wet Age-related Macular Degeneration
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Sign the consent form, willing and able to comply with clinic visits and study-related procedures;
  • 50 years of age or older;
  • Diagnosed with wAMD;
  • Active CNV lesion of any type (ie, predominantly classic, minimally classic, or occult [including polypoidal choroidal vasculopathy and retinal angiomatous proliferation]) that exhibits all of the following characteristics:

    • The CNV or sequela of the CNV affect the foveal;
    • A total lesion size of ≤12 disc areas on FFA;
    • Evidence of CNV leakage on FFA;
    • Intra and/or subretinal fluid confirmed on OCT;
  • BCVA of 78-19 letters using the ETDRS protocol;
  • Sufficiently clear ocular media and adequate pupillary dilatation to allow acquisition of good-quality retinal images to confirm diagnosis.

Exclusion criteria

Exclusion Criteria:

For the study eye:

  • CNV due to causes other than AMD, such as ocular histoplasmosis, trauma, pathological myopia, angioid streaks, choroidal rupture, or uveitis;
  • Any history of macular pathology unrelated to AMD affecting vision or contributing to the presence of intraretinal or subretinal fluid;
  • Presence at screening of central serous chorioretinopathy;
  • Retinal pigment epithelial tear involving the foveola on day 1;
  • Fibrosis or atrophy involves the foveola;
  • Subretinal haemorrhage involves the foveola;
  • Any concurrent intraocular condition (eg, amblyopia, aphakia, retinal detachment, cataract, diabetic retinopathy or maculopathy, or epiretinal membrane with traction) that, in the opinion of the investigator, could either reduce the potential for visual improvement or require medical or surgical intervention during the study;
  • Current vitreous hemonhage or history of vitreous hemorrhage in the study eye within 4 weeks prior to baseline;
  • Uncontrolled glaucoma;
  • Spherical equivalent of refractive error demonstrating ≥8 diopters of myopia;
  • Previous treatment with anti-VEGF therapy within the 3 months period prior to baseline;
  • Intraocular use of long-acting during the 6 month period prior to baseline; intraocular use of short or medium-acting corticosteroids during the 3 month period prior to baseline; periocular use of corticosteroids during the 1 month period prior to baseline;
  • Use of topical ocular corticosteroids for 60 or more consecutive days within the 3 month period prior to baseline;
  • Macular laser treatment, PDT, TTT or other surgical intervention for AMD within the 3 month period prior to baseline;
  • Any cataract surgery or treatment for complications of cataract surgery with steroids within the 3 month period prior to baseline; YAG laser capsulotomy within 1 month before baseline;
  • Aphakia or pseudophakia with absence of posterior capsule, unless it occurred as a result of YAG posterior capsulotomy;
  • Intraocular or refractive surgery within the 3 month period prior to baseline;
  • Previous penetrating keratoplasty or vitrectomy or panretinal photocoagulation or radiotherapy;

For the fellow eye or both eyes:

  • Non-functioning non-study eye;
  • Treatment with anti-VEGF therapy within the 7 day period prior to baseline in the nonstudy eye;
  • Any history of idiopathic or -associated uveitis in either eye;
  • Current active ocular inflammation or suspected or active ocular or periocular infection in either eye;

General exclusion criteria:

  • Any major illness or major surgical procedure within 1 month before screening;
  • Active cancer within the past 12 months except for appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, and prostate cancer with a Gleason score of \<6 and a stable prostate-specific antigen for >12 months;
  • Requirement for continuous use of any medications and treatments indicated as prohibited therapy;
  • Systemic anti-VEGF therapy within the 3 month period prior to baseline;
  • Use of systemic corticosteroids for 30 or more consecutive days within the 3 months prior to baseline, with the exception of low stable doses of corticosteroids (defined as ≤10 mg/day prednisolone or equivalent dose);
  • Systemic treatment for suspected or active systemic infection on baseline;
  • COVID-19 infection within the 4 week period prior to screening; Hospitalization required severe COVID-19 infection within the 12 month period prior to screening;
  • (+) and HBV DNA>;
  • antibody(+); antibody(+); active syphilitic patients;
  • Uncontrolled blood pressure, defined as systolic blood pressure >180 mmHg and/or diastolic blood pressure >100 mmHg;
  • Stroke (cerebral vascular accident) or myocardial infarction within the 6 month period prior to baseline;
  • History of other disease, metabolic dysfunction, physical examination finding, or historical or current clinical laboratory finding giving reasonable suspicion of a condition that contraindicates the use of the drug or that might affect interpretation of the results of the study or renders the patient at high risk for treatment complications in the opinion of the investigator;
  • Pregnancy or breastfeeding, or intention to become pregnant during the study;
  • History of a severe allergic reaction or anaphylactic reaction to a biologic agent or known to any component of RC28-E or to aflibercept injections, study-related procedure preparations (including fluorescein), dilating drops, or any of the anaesthetic and anti-microbial drops used by the patient during the study;
  • Participation in an investigational trial that involves treatment with any drug or device (with the exception of vitamins and minerals) within the 3 month period prior to baseline.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
432 participants (estimated)

Study arms

  • Experimental
    RC28-E

    RC28-E 2 mg will be initially injected 3 times at 4 week intervals, then each subject will be injected every 12 weeks unless there is disease activity. If disease activity is identified, the subject will be reassigned to receive injections every 8 weeks thereafter, up to study exit.

    Drug: RC28-E

  • Active comparator
    Aflibercept

    Aflibercept 2 mg will be injected 3 times at 4 week intervals, followed by injections every 8 weeks.

    Drug: Aflibercept

Interventions

  • DrugRC28-E

    Ophthalmic solution for intravitreal injection administered as a 2.0mg/50 µL dose.

  • Ophthalmic solution for intravitreal injection administered as a 2.0mg/50 µL dose.

    Also known as: Eylea

06

What researchers measure

Primary outcomes

  1. Mean change from baseline in BCVA at week 48;

    BCVA=Best-corrected visual acuity; Measurement of visual acuity with Early Treatment Diabetic Retinopathy Study (ETDRS) charts.

    Time frame: Baseline, week 48

Secondary outcomes

  1. Average change in BCVA from baseline over the period week 36 through week 48;

    For each subject, this endpoint is defined as the average of the changes from Baseline to Weeks 36, 40, 44 and 48.

    Time frame: Baseline, weeks 36, 40, 44 and 48.

  2. Proportion of subjects with q12w injection;

    q12w=every 12 weeks

    Time frame: Baseline, week 48

  3. Proportion of subjects with q12w injection at week 48 within the subjects with no q8w injection need at week 16, week 20;

    for subjects randomized to RC28-E group only; q12w=every 12 weeks; q8w=every 8 weeks; A disease activity assessment (DAA) was performed at pre-specified visits (Weeks 16, 20, 28, 32, 40, 44) to identify q8w injection need.

    Time frame: Week 16, 20, 48

  4. Proportion of subjects with gain in BCVA of 15/10/5/0 letters or more from baseline to week 48;

    Proportion of subjects; BCVA=Best-corrected visual acuity;

    Time frame: Baseline, week 48

  5. Mean change in CST from baseline to week 16, week 48;

    CST=Central retinal subfield thickness

    Time frame: Baseline, week 16, 48

  6. Average change in CST from baseline over the period week 36 through week 48;

    CST=Central retinal subfield thickness

    Time frame: Baseline, weeks 36, 40, 44 and 48.

  7. Proportion of subjects with presence of intraretinal fluid/subretinal fluid at week 16, week 48;

    Intraretinal fluid was assessed using SD-OCT and recorded as Present/Absent. Subretinal fluid was assessed using SD-OCT and recorded as Present/Absent. The presence of intraretinal fluid/subretinal fluid is an indicator of underlying disease.

    Time frame: Baseline, week 16, 48

  8. Percentage of subjects with disease activity present at week 16;

    A disease activity assessment (DAA) was performed to identify q8w injection need. 95% confidence interval (CI) for binomial proportions is based on Clopper-Pearson exact method. One eye (study eye) contributed to the analysis. Hypothesis testing not pre-specified.

    Time frame: Baseline, week 16

  9. Change in choroidal neovascularization (CNV) lesion size from baseline to week 12, week 48;

    CNV lesion size (the area of new blood vessels in the choroid layer of the retina) was measured using fundus fluorescein angiography (FFA). A negative change value indicates a reduction in lesion size, whereas a positive change value indicates an increase. An increase in CNV lesion size may indicate progression of the underlying disease. Only one eye (study eye) contributed to the analysis.

    Time frame: Baseline, week 12, 48

  10. Proportion of subjects with q8w treatment need at weeks 16, 20, 28, 32, 40, 44;

    q8w=every 8 weeks; A disease activity assessment (DAA) was performed at pre-specified visits (Weeks 16, 20, 28, 32, 40, 44) to identify q8w need. This outcome measure was pre-specified for RC28-E arm only.

    Time frame: Weeks 16, 20, 28, 32, 40, 44

  11. Incidence and characteristics of ocular and systemic treatment emergent adverse events.

    safety endpoint

    Time frame: Baseline, week 48

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2023 (actual). Primary completion is estimated for Nov 2025, 32 months after the start.

Of 77 industry-sponsored phase 3 interventional studies under Macular Degeneration, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 33. This study's planned 32 months is above that.

Counting every sponsor, half of 83 studies reached it within 24 months; a quarter within 20 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 10, 2023
First posted
Feb 14, 2023
StartActual
Mar 14, 2023
Primary completionEst.
Nov 29, 2025
CompletionEst.
Dec 29, 2025
Last update
Aug 31, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 31, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05727397
Lead sponsor
RemeGen Co., Ltd.
Responsible party
Sponsor
First posted
Feb 14, 2023
Start date
Mar 14, 2023
Primary completion
Nov 29, 2025 (estimated)
Completion
Dec 29, 2025 (estimated)
Last update
Aug 31, 2023

Study contacts

Binghua Xiao
Contact
xiaosir522@163.com
86-010-58076833

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: RC28-E protein

Start the discussion